INVO Fertility, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
INVO Fertility reported Q3 2026 clinic revenue of $2.21M (up 28% YoY from $1.72M), with consolidated revenue at $2.22M (+26% YoY). Clinic-Level Adjusted EBITDA reached $292K (vs. $243K YoY), marking the seventh consecutive profitable quarter at clinic level before corporate expenses. The company made two acquisitions: Indiana clinic (Feb 2026, full quarter in Q3) and Birmingham clinic (June 2026, acquired remaining 50% for $175K payable). Cash position improved to $3.7M ($3.10/share; 1.19M shares outstanding) with current liabilities reduced to $4.5M from $10.3M year-end 2025. Net loss narrowed to $2.1M from $3.4M YoY.
Why this rating
Meaningful revenue growth and clinic profitability in small-cap context, but company remains unprofitable at GAAP level ($2.1M loss). Modest absolute clinic contribution relative to $2.2M market cap and improving balance sheet offset by ongoing corporate losses.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.